References
- Van OJ, Kapur S. Schizophrenia. Lancet 2009;374:635-45
- Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
- Zhu B, Ascher-Svanum H, Faries DE, et al. Costs of treating patients with schizophrenia who have illness-related crisis events. BMC Psychiatry 2008;8:72-81
- Schizophrenia. National Institute of Mental Health. http://www.nimh.nih.gov/health/publications/schizophrenia/schizophrenia-booket-2009.pdf. Accessed September 16, 2013
- Almond S, Knap M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004;184:346-51
- Karve SJ, Panish JM, Dirani RG, et al. Health care utilization and costs among Medicaid-enrolled patients with schizophrenia experiencing multiple psychiatric relapses. Health Outcomes Res Med 2012;3:183-94
- Chen EY, Hui CL, Dunn EL, et al. A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophrenia Res 2005;77:99-104
- Brown JD, Barrett A, Ireys H, et al. Evidence-based practices for Medicaid beneficiaries with Schizophrenia and Biopolar disorder. No. 7490. Mathematica Policy Research, 2012. http://aspe.hhs.gov/daltcp/reports/2012/ebpsbd.shtml. Accessed November 6, 2013
- Seal KH, Berenthal D, Miner CR, et al. Bringing the war back home: mental health disorders among 103 788 US veterans returning from Iraq and Afghanistan seen at Department of Veterans Affairs facilities. Arch Intern Med 2007;167:476-82
- United States Department of Veterans Affairs. VA medical centers. http://www.va.gov/health/. Accessed September 16, 2013
- Xie L, Baser O. Clinical and economic burden of U.S. veteran schizophrenia patients: a real-world evaluation. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting. New Orleans, LA: May 18-22, 2013
- Marder SR. Effective treatment for schizophrenia. United States Department of Veterans Affairs, http://www.hsrd.research.va.gov/publications/internal/pm_v7_n1.pdf. Accessed Sept 16, 2013
- Mohamed S. Adaptation of intensive mental health intensive case management to rural communities in the Veterans Health Administration. Psychiatric Q 2013;84:103-14
- O’Connor N. Book review: antipsychotic long-acting injections. Aust Psychiatry 2013;21:176-7
- Schizophrenia 2013. DR/Decision Resources, LLC., Burlington, MA. 2013.
- Achilla E, McCrone P. The cost-effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl Health Econ Health Policy 2013;11:95-106
- Fuller M, Shermock K, Russo P, et al. Hospitalisation and resource utilization in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J Med Econ 2009;12:317-24
- Lafeuille MH, Gravel J, Lefebvre P, et al. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Medl Econ 2013;16:1290-9
- Kozma, CM, Slaton T, Dirani R, et al. Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open label extension. Curr Med Res Opin 2011;27:1603-11
- Garcia-Ruiz AJ, Perez-Costillias L, Montesinos AC, et al. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. Health Econ Rev 2012;2:8-19
- Edwards NC, Rupnow MF, Pashos CL, et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. PharmacoEconomics 2005;23:299-314
- Geitona M, Kousoulakou H, Ollandezos M, et al. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Ann Gen Psychiatry 2008;7:16-27
- Zhornitsky S, Strip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophrenia Res Treat 2012;2012:7171-82
- Olivares JM, Rodriquez-Martinez A, Buron JA, et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12-and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008;6:41-53
- Lamoreaux J. The organizational structure for medical information management in the Department of Veterans Affairs. An overview of major health care databases. Med Care 1996;34:31-44
- Imbens GW. Nonparametric estimation of average treatment effects under exogeneity: a review. Rev Econ Stat 2004;86:4-29